MetaCap

MiNK Therapeutics (INKT) vs Instil Bio (TIL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MiNK Therapeutics (INKT) has outperformed Instil Bio (TIL) over the past year, losing 24.1% versus a loss of 60.2%. Over five years, INKT leads with a -96.0% price change compared with -98.7% for TIL. MiNK Therapeutics is the larger company by market cap ($41.2 million vs $35.5 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

INKT-24.05%TIL-60.20%
+39%-13%-65%
Nov 21, 20251 yearNov 20, 2026
INKT-94.98%TIL-98.82%
+31%-37%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

INKT versus TIL key metrics
MetricINKTTIL
Share price$8.02$5.23
Market cap$41.17M$35.47M
1-day change-6.85%-5.77%
YTD return-28.07%-52.45%
1-year return-24.05%-60.20%
5-year return-95.99%-98.72%
EPS (TTM)$-2.23$-3.09
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$10.77M
Revenue growth (YoY)—+152.38%
Net income (latest FY)$-12.49M$-71.37M
Operating margin—-745.39%
Net margin—-662.75%
52-week high$16.93$12.92
52-week low$7.76$5.14
Distance from 52-week high-52.62%-59.51%
Analyst consensusstrong_buynone
Avg. price target upside+386.28%+33.84%
Average volume15.74K42.02K
Shares outstanding5.13M6.78M
Employees1517
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • INKT has outperformed TIL by 36.1 percentage points over the past year.

About MiNK Therapeutics

INKT stock →

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS).

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 15 employees

About Instil Bio

TIL stock →

Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees

INKT vs TIL FAQ

Which is bigger, MiNK Therapeutics or Instil Bio?

MiNK Therapeutics (INKT) is larger, with a market capitalization of $41.17M compared with $35.47M for Instil Bio (TIL).

Which stock has performed better over the past year, INKT or TIL?

INKT returned -24.05% over the past 12 months, compared with -60.20% for TIL (price return, excluding dividends). Past performance does not predict future results.

Are MiNK Therapeutics and Instil Bio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons